Scarica l'app Stockscreener
1.99
10.56%
0.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CABA Giù?
Forum
Previsione
Cabaletta Bio Inc Borsa (CABA) Ultime notizie
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN
Cabaletta Bio stock price target reiterated on strong clinical data By Investing.com - Investing.com India
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock - Investing.com Australia
Cabaletta Bio’s (CABA) Buy Rating Reaffirmed at HC Wainwright - Defense World
Analysts Offer Predictions for Cabaletta Bio FY2026 Earnings - Defense World
Cabaletta Bio Launches Public Offering Of Stock And Warrants - Nasdaq
Cabaletta Bio (CABA) Shares Drop 20% After Public Offering Annou - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants By Investing.com - Investing.com South Africa
Cabaletta reports positive clinical data for autoimmune cell therapy By Investing.com - Investing.com South Africa
Cabaletta Bio looks to raise $100M in stock sale to fund cell therapy development - The Business Journals
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wainwright & Co. | CABA Stock News - GuruFocus
Cabaletta Bio shares CAR-T results in three autoimmune conditions - Endpoints News
Cabaletta Bio Prices Securities Offering; Shares Fall - marketscreener.com
Cabaletta Bio stock tumbles after pricing $100 million public offering - Investing.com Australia
Cabaletta Bio Announces Pricing of Public Offering of Securities - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants - Investing.com
Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction - Seeking Alpha
Cantor Fitzgerald Predicts Cabaletta Bio FY2026 Earnings - MarketBeat
Cabaletta Bio announces public offering of common stock and warrants - Investing.com
Cabaletta Bio (CABA) Launches Public Offering with Warrants | CABA Stock News - GuruFocus
Cabaletta Bio (CABA) Showcases Promising Rese-cel Data at EULAR 2025 | CABA Stock News - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities | - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities - The Manila Times
Cabaletta Bio Announces Proposed Public Offering of Securities | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress | CABA Stock News - GuruFocus
Autoimmune Disease Pioneer Cabaletta Bio Announces Major Public Offering With Jefferies Leading - Stock Titan
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - The Manila Times
Cabaletta reports positive clinical data for autoimmune cell therapy - Investing.com
Breakthrough: New Autoimmune Therapy Achieves Drug-Free Remission in 94% of Trial Patients - Stock Titan
Cabaletta Bio Stockholders Approve Key Proposals - TipRanks
Squarepoint Ops LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Millennium Management LLC Has $1.16 Million Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Wellington Management Group LLP Grows Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
CrowdStrike Stock Drops on Cautious Outlook -- Is This a Buying Opportunity? - The Globe and Mail
Two Sigma Investments LP Has $1.71 Million Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Bank of America Corp DE Buys 67,787 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Down 40% This Year, Is UnitedHealth Group's Dividend in Danger? - The Globe and Mail
Millennium Management LLC Sells 1,217,300 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Two Sigma Investments LP Boosts Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Two Sigma Advisers LP Has $1.89 Million Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
BNP Paribas Financial Markets Acquires Shares of 51,952 Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Jefferies Global Healthcare Conference 2025 - MSN
Northern Trust Corp Sells 5,849 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Cabaletta Bio Showcases First-Ever Curative Autoimmune Cell Therapies at Major Jefferies Conference - Stock Titan
D. E. Shaw & Co. Inc. Sells 17,359 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN
Point72 Asset Management L.P. Acquires 598,607 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Announces Quarterly Earnings Results - MarketBeat
Cantor Fitzgerald Predicts Weaker Earnings for Cabaletta Bio - MarketBeat
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):